Cipher’s tramadol cleared by Health Canada

Cipher Pharmaceuticals (TSX:DND) has received Health Canada approval for its CIP-Tramadol ER, an extended-release treatment of moderate to moderately severe chronic pain in adults. “This represents the second regulatory approval for our extended-release tramadol and another important milestone for the company,” CEO Larry Andrews said in a statement. “We believe our product’s unique attributes, including [...]

Cipher completes CIP-Isotretinoin enrolment

Cipher Pharmaceuticals (TSX:DND) has completed patient enrolment in a Phase 3 safety study of its CIP-Isotretinoin treatment of severe, nodular acne. A total of 931 patients were enrolled in the trial, of which 626 have completed treatment to date. Following an estimated six-month treatment period, the last subject enrolled should complete treatment in April, 2011, [...]

Cipher readying tramadol launch in first quarter 2011

Cipher Pharmaceuticals (TSX: DND) is “working diligently” to finalize a marketing partnership and is finalizing commercial manufacturing requirements for its extended-release tramadol drug, which was cleared by the FDA in the second quarter, as it prepares for a commercial launch expected in the first quarter of 2011. The company also disclosed in its second quarter [...]

Cipher gets sales milestone for Lipofen

Cipher Pharmaceuticals‘ (TSX:DND) Lipofen fenofibrate product reached a cumulative sales milestone, triggering a $1 million (U.S.) milestone payment from Kowa Pharmaceuticals America, Cipher’s U.S. marketing and distribution partner. The milestone payment will be reflected in Cipher’s revenue for the second quarter of fiscal 2010. “Kowa continues to do an excellent job with the promotion of [...]

Cipher plans to license-in new drug this year

For much of its six years as a separate company, Cipher Pharmaceuticals (TSX:DND) has been known for driving its three drugs toward the finish line.  That could change in 2010. “We ramped up our in-house resources last year to look at adding pipeline opportunities, and we’ve looked at over 100 to this stage,” CEO Larry Andrews [...]

« Previous Page